Aethon Therapeutics, Inc. — Form D
Aethon Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2022-12-22. The offering totals $30.0M, of which $6.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-12-22
- Form: D
- Accession: 0001958956-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $30.0M
- Amount sold: $6.0M
- Remaining: $24.0M
- Investors: 2
- Date of first sale: 2022-12-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-468421
Issuer
- Name: Aethon Therapeutics, Inc.
- CIK: 0001958956
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 230 PARK AVENUE, NEW YORK, NY, 10169
- Phone: 857-352-3657
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Rajesh Chopra | Director | Larkspur, CA |
| Paul Da Silva Jardine | Director | New York, NY |
| Seth Harrison | Director | Redwood City, CA |
| Rajesh Chopra | Executive Officer | Larkspur, CA |
| Paul Da Silva Jardine | Executive Officer | New York, NY |
| William Engels | Executive Officer | New York, NY |
More